Skip to Main Content

Efficacy and Safety of the Tx360® Nasal Applicator for Transnasal Sphenopalatine Ganglion Block

Conditions

Diseases of the Nervous System | Men's Health | Women's Health

Phase III

What is the purpose of this trial?

To be considered for participation in this research study, you must have a history of chronic migraine headaches. We will be testing a new treatment which may help your migraine headaches not to hurt as much, and may prevent the number of times you have migraine headaches each month. This treatment involves a drug called bupivacaine, which is an anesthetic and a plastic medical device, called Tx360®. Bupivacaine and Tx360® are both commercially available.


Total study duration for each subject is 20 weeks including a 28-day screening/baseline phase, a four week treatment phase, and 3 month follow-up phase.

  • Trial with
    Tian Medical
  • Start Date
    05/29/2018
  • End Date
    12/30/2018
Trial Image

For more information about this study, contact:

Elizabeth Perrotti

I'm interested in volunteering

If you would prefer to contact a member of the Help us Discover team about this trial and other similar trials, please email helpusdiscover@yale.edu or call 877.978.8343

  • Last Updated
    08/19/2018
  • Study HIC
    #2000022129